Project Oncology®

In light of the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Lola Fayanju, an Associate Professor of Surgery and Population Health Sciences at Duke University School of Medicine, shares with us some of the updates in breast cancer care amid the COVID-19 pandemic that she’s most excited to learn more about at the conference.

Here to examine the updated ASCO and CAP joint guidelines and their recommendations in the ongoing mission to improve the accuracy of HER2 testing is Dr. Oudai Hassan.

In light of the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Lola Fayanju, an Associate Professor of Surgery and Population Health Sciences at Duke University School of Medicine, shares with us some of the updates in breast cancer care amid the COVID-19 pandemic that she’s most excited to learn more about at the conference.

Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.

Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.

Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.

With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.

After starting on a RET inhibitor, what do you do? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, breaks down the progression of RET inhibitors in patients with non-small cell lung cancer and what tests should be utilized throughout the process.

Once we identify RET fusion abnormalities in patients with non-small cell lung cancer, what targeted therapies are available to us? Tune in to hear Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center, share a brief overview of targeted therapies for patients with RET-rearranged non-small cell lung cancer.

Here to give us a look at the unique genetic characteristics and prognostic implications for male and female patients with non-small cell lung cancer who harbor the RET fusion gene is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

What do we need to know about the Microscaled Proteogenomic Analysis method and the potential impacts of providing detailed tissue analyses from single-core needle biopsies? Here to talk about this new diagnostic tool for breast cancer is Dr. Matthew Ellis, Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine.